






































Investigations on the Pharmacology of the Cardioprotective
Guanidine ME10092
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Abstract: The guanidine compound ME10092 (1-(3,4-dimethoxy-
2-chlorobenzylideneamino)-guanidine), which possesses a strong
cardioprotective effect to ischemia-reperfusion, was assessed for dif-
ferent pharmacological actions that may underlie its cardioprotective
effect. In the living rat ME10092 decreased the blood pressure and
heart rate in a dose-dependent manner. We found ME10092 to bind
to 1- and 2-adrenoreceptors with moderate affinity (Ki values 1–4
µM), and to block adrenaline-elicited contractile responses in isolated
guinea pig aortas. Our results indicate that ME10092 possesses a cer-
tain anti-oxidant profile. Thus, in a competitive manner and with low
affinity it inhibited the bovine milk xanthine oxidase enzyme, as well
as NAD(P)H oxidase driven oxyradical formation in membrane frac-
tions isolated from the rat brain. By using electron paramagnetic reso-
nance we here show that, after its systemic administration, ME10092
modulates the nitric oxide (NO) content in several tissues of the rat in
a time-dependent manner. However, in vitro ME10092 inhibited the
activities of nitric oxide synthases nNOS and eNOS, but not that of
iNOS. Our data give evidence that the cardioprotective effect of
ME10092 could be mediated through pharmacological mechanisms
that include some modulation of NO production, as well as possible
inhibition of radical formation during ischemia-reperfusion.
Key Words: guanidine, xanthine oxidase, adrenoreceptor, NAD(P)H
oxidase, nitric oxide synthase
(J Cardiovasc Pharmacol™ 2004;44:178–186)
The complexity of ischemia and reperfusion-mediated bio-chemical events in the heart offers multiple possibilities
for pharmacological intervention. Free radicals are generated
by several enzyme systems (eg, xanthine oxidase, NAD(P)H
oxidases, nitric oxide synthases (NOSs)) during reoxygenation
following an ischemic period of the heart, and constitute a ma-
jor factor causing abnormalities in cardiac functioning.1,2 In-
ability of cellular membranes to maintain an ionic balance, as
well as insufficient energy metabolism, also leads to the final
pathways of tissue injury.
In our earlier studies, we found that an electron acceptor-
inhibitor of xanthine oxidase, the N-hydroxy-compound PR5
(1-(3,4-dimethoxy-2-chlorobenzylideneamino)-3-hydroxy-
guanidine)), possesses a remarkable cardioprotective effect,
when administered to rats subjected to left coronary artery
clamping followed by reperfusion.3,4 Later we showed that
ME10092, which is a guanidine metabolite to PR5, also exerts
a similar cardioprotective action.5 We found that the adminis-
tration of ME10092 to rats subjected to 1 hour left coronary
occlusion followed by 2 hours reperfusion reduced the heart
infarction size by approximately 40%.5 Moreover, ME10092
prevented the marked drop in mean arterial pressure seen dur-
ing the reperfusion phase. In addition to these effects,
ME10092 appeared to have a direct action on the heart as it
caused a dose dependent but transient reduction in the heart
rate and a slight and transient reduction in mean arterial blood
pressure.5
We also showed that both PR5 and ME10092 are xan-
thine oxidase inhibitors.6 Moreover, we found that PR5 be-
comes completely and rapidly metabolized to ME10092 in
vivo as determined in rat serum after oral administration of the
drug.5 In view of the latter finding, and due to the practically
indistinguishable pharmacological effects of PR5 and ME10092,
we suggested that the cardioprotective effect of PR5 is medi-
ated by a direct effect afforded by its metabolite, ME10092.5
The present study was undertaken to clarify the bio-
chemical mechanisms underlying the cardioprotective effect
of ME10092. We have here evaluated ME10092 for adrener-
gic activities, as several guanidine compounds structurally re-
lated to ME10092 are known to possess these properties.7
Moreover, in addition to characterization of xanthine oxidase
inhibitory activity, we also evaluated ME10092 for different
antioxidant, ie, oxyradical and nitric oxide producing enzymes
blocking properties in biochemical and in vivo test systems.
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METHODS
Animals
Male Wistar rats weighing 200 to 300 g were housed
under standard conditions (21–23°C, 12-hour light:dark cycle)
with unlimited access to food and water. All experimental pro-
cedures were performed in accordance with the regulations of
the Animal Ethical Committee of BaltLASA, Riga, Latvia, and
Local Ethics Committee for Animal Experiments, Uppsala,
Sweden. This investigation also conforms to the Guide for the
Care and Use of Laboratory Animals published by the US Na-
tional Institutes of Health (NIH Publication No 85-23, revised
1985).
Drugs
Pentobarbital sodium was from Richter Pharma (Wien,
Austria), N-(3,4-Dimethoxy-2-chlorobenzylideneamino)-
guanidine (ME-10092, in some earlier studies also termed
PR9) was synthesized by Nordic Synthesis, (Karlskoga,
Sweden). [3H]-prazosin (91 Ci/mmol), [3H]-RX821002
(58 Ci/mmol) and L-[2,3,4,5-3H]arginine HCl (53,4 Ci/mmol)
were from Amersham Pharmacia Biotech. Dipheniliodonium
(DPI), diethylenetriaminepentaacetic acid (DTPA), DMA
(5-(N,N-dimethyl)amiloride), Tris-HCl, KH2PO4, phenyl-
methylsulfonyl fluoride (PMSF), propranolol, diethylthiocar-
bamate, L-nitroarginine methylester (L-NAME), TBAHSO4
(Tetrabutyl Ammonium Hydrogen Sulfate) were from Sigma
(St. Louis, MO). Ketamine was from Alfasan (Woeirden, Hol-
land) and xylazine was from Bioveta AS (Ivanovice na Hane,
Czech). Bovine milk xanthine oxidase, recombinant NOS bo-
vine endothelial (eNOS), rat neuronal (nNOS), and mouse in-
ducible (iNOS) (specific activity 0,3; 300 and 7 units/mg pro-
tein, respectively) were from Sigma (St. Louis, MO).
Blood Pressure and Heart Rate Measurements
Male Wistar rats (250–300 g) were anesthetized with ke-
tamine 70 mg/kg and xylazine 10 mg/kg. Blood pressure was
recorded by a transducer connected to the carotid artery. Heart
rate was continuously computed from the blood pressure pulse
wave using Quad Bridge Amp and PowerLab/400 (AD Instru-
ments). A femoral vein was cannulated for peripheral drug
administration.
Isolated Aorta Preparations
Male guinea pigs (350–450 g) were killed by decapita-
tion. Their aortas were removed, and placed in 37°C warm
modified Krebs-Henseleit solution (in mM: 2.5 CaCl2, 11.1 glu-
cose, 4.7 KCl, 1.2 KH2PO4, 1.2 MgSO4, 118.0 NaCl, and 25.0
NaHCO3, 1 µM ketoprofen) equilibrated with 95% O2–5%
CO2. After removal of adjacent tissue from the aortas, rings of
2 to 3 mm of length were prepared using a pair of scissors.
Each ring was then mounted into an organ bath and tied to an
isometric MLT050 force transducer (AD Instruments), using a
pair of cotton threads inserted through the lumen of the ring.
The preparation was given an initial tension of 10 mN. When
ME10092 was present it was added 15 minutes prior to the
addition of (-)adrenaline. The contractile force was recorded
using ADInstruments Tech ware system equipped with a
QUAD ML-118 bridge amplifier and PowerLab 400, con-
nected to a PowerMac computer. Data were calculated and
plotted using GraphPad Prism 3.0 and Chart 4.0 for Windows
software.
Electrically Stimulated Guinea Pig Ileum
Coaxial electrical stimulation of the ileum was per-
formed essentially as described.8 In brief, 2-cm ileum pieces
were mounted in organ bath with an electrode inserted into the
lumen and another in contact with the surrounding Krebs-
Henseleit solution (for composition see above). Electrical
stimulation was given with 1 millisecond pulses at 0.1 Hz us-
ing a voltage just above that which gave a maximal response.
During these conditions twitch contractions are elicited, which
are mediated via the stimulation of release of acetylcholine
from intramural cholinergic neurons. Moreover, these twitch
contractions can be inhibited by adrenergically active agonists
such as (-)noradrenaline, by an action on prejunctional 2-
adrenoceptors situated in the cholinergic neurons.8
Expression of the Human 1A-Adrenoceptor
in COS1 Cells, and Human 2A-, 2B-,
and 2C-Adrenoceptors in Insect Sf9 cells,
and Radioligand Binding Assays
The human 1A-, 2A-, 2B-, and 2C-encoding genes
were cloned as described.9,10 Radioligand binding was per-
formed essentially as described.9 Membranes expressing
human 1A-adrenoceptor (150 µL in final suspension) were
incubated with 0.7 nM [3H]-prazosin, and different concen-
trations of ME10092. Similarly, membranes expressing
the human 2A-,  2B, or  2C-adrenoceptors were incubated
with 1 nM [3H]-RX821002 and different concentrations of
ME10092 (1 nM–1 mM). After filtering and washing on glass-
fiber filters, the radioactivity retained on each filter was
counted. The potencies of the tested drugs to displace the ra-
dioligands from the receptors were calculated from the data
using law of mass action computer modeling with the BindAid
software (Wan System).
Xanthine Oxidase Activity
The activity of xanthine oxidase was determined by as-
saying uric acid formation in a reaction mixture containing
0.005 units/ml of bovine milk xanthine oxidase, various con-
centrations of xanthine, and ME10092 in 50 mM Tris-HCl pH
7.4 at 25°C. The samples were preincubated with ME10092 for
5 minutes before starting the reaction by addition of xanthine.
After 5 minutes the reaction was quenched by addition of ice-
cold methanol (1:1 vol/vol). The concentration of uric acid in
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the samples was determined by HPLC on a 250 × 4.6 mm All-
tech Select-B RP column. Mobile phase: linear gradient from
5% MeOH in 0.05M KH2PO4 (pH = 5.6, 0.05M TBAHSO4) to
42% MeOH in 0.05M KH2PO4 (pH = 5.6, 0.05M TBAHSO4),
flow rate 1 ml/min, detection—UV at 291 nm, runtime—45
minutes. LOD of the procedure—3.3 mM/L of uric acid.
Measurement of Lucigenin–Derived
Chemiluminescence in Rat Brain Membranes
Rat brain membranes were isolated essentially as de-
scribed previously.11 In brief, rat forebrains were homog-
enized at 1500 rpm for 1 minute with a glass-Teflon homog-
enizer in ice-cold homogenization buffer (250 mM sucrose, 10
mM HEPES, 1 mM EDTA, 0.1 mM PMSF, 0.5% w/v bovine
serum albumin, pH 7.4) at w/v ratio 1:20. The crude homog-
enate was spun at 500 × g for 10 minutes. The supernatant was
then centrifuged at 17 500 × g for 20 minutes at 4°C and
the pellet re-suspended in isotonic PBS, pH 7.4, containing
0.1 mM DTPA. The final protein concentration was adjusted to
4 mg/ml. The lucigenin reaction was carried out in 96-well
Isoplates™ (Wallac Finland) at +37°C. ME10092 was incu-
bated with the rat brain membranes (protein concentration
1 mg/ml) for 15 minutes. After that NAD(P)H (0.2 mM) and
lucigenin (5 µM) were added and the luminescence immedi-
ately counted using a Wallac MicroBeta TriLux liquid scin-
tillation and luminescence counter. Luminescence in the blank
samples (without cofactor) was less than 5% of control lev-
els, which was subtracted from the luminescence readings of
the test samples. Each data point represents average of 3 to 5
assays.
EPR Determination of Nitric Oxide in Rat
Tissues after ME10092 Administration
The NO contents of rat brain, liver, heart, and testis were
determined as described previously.12,13 The experiment was
started by an i.p. administration of saline or ME10092 in saline
(5 and 10 mg/kg) to, respectively, control and ME10092
treated rats. Animals were killed and tissue samples frozen in
liquid nitrogen 0.5 hours after spin trap agent administra-
tion.12,13 EPR spectra were recorded by a Radiopan SE/X2544
EPR spectrometer. Measurement parameters were as follows:
X-band operation, 25 mW, 9.24 GHz microwaves, 100 kHz
modulation frequency, 5 G modulation amplitude, 2.5 mW mi-
crowave power, 5 × 10−5 receiver gain, time constant 1 second.
NO concentration (ng/g of tissue) was calculated from an
NaNO2 calibration curve.
Nitric Oxide Synthase Activity Determination
Nitric oxide synthase activities were determined us-
ing a method based on the conversion of L-[3H]arginine to
L-[3H]citrulline. NOS isoforms (eNOS, nNOS, iNOS) were in-
cubated in 25 mM Tris buffer (pH 7.4) for 30 minutes at 37°C
in the presence of 1 mM NADPH, 100 µM H4B, 10 µM FAD,
10 µM FMN, 1.5 mM CaCl2, 2 µg/ml calmodulin, and 2.5 µM
L-[3H]arginine (approximately 100 000 dpm of L-[2,3,4,5-
3H]arginine HCl) and appropriate concentration of inhibitors
(ie, ME10092 and L-NAME). The reaction was terminated by
adding 0.6 mL Dowex-50W Tris form, equilibrated in 50 mM
HEPES buffer (pH 5.5), containing 1 mM citrulline and 5 mM
EDTA. After 1 hour incubation at room temperature, the solu-
tion was collected into OptiPhase SuperMix (Wallac) scintil-
lation liquid and the radioactivity counted in a Rackbeta 1217
liquid scintillation counter. NOS activity was expressed as the
amount of citrulline formed.
Statistical Analysis
The results are presented as the mean ± SEM. Statistical
analysis was performed using unpaired two-tailed Student
t test. Results were considered as significant when P  0.05.
RESULTS
Effects on Blood Pressure and Heart Rate
As can be seen from Figure 1A and 1B, ME10092 in-
duced clear hypotensive and bradycardic effects in the anes-
thetized adult rat. Thus, i.v. injections of ME10092 (1–10
mg/kg) dose dependently and significantly decreased diastolic
blood pressure and heart rate. At the dose of 10 mg/kg the drop
amounted to maximally 50% for both diastolic pressure (from
initial 76 mm/Hg to 37 mm/Hg) (Fig. 1A) and heart rate (from
initial 315 BPM to 189 BPM) (Fig. 1B). However, the systolic
blood pressure was not influenced by ME10092, although
there seemed to be a tendency toward lowered pressure. The
effect on blood pressure lasted for approximately 30 seconds.
Interestingly, the effect on heart rate followed a distinct pat-
tern, with an initial fast drop (30 seconds) followed by some
regain, which was then followed by a sustained gradual drop of
heart rate until a plateau was reached and sustained for more
than 30 minutes (Fig. 1C). (Statistical comparisons for the ef-
fect of ME10092 were in all above cases performed versus
injection of saline, where the saline injections per se induced
virtually no effects.)
-Adrenergic Activities of ME10092
in Isolated Organs
The in vitro -adrenergic activity of ME10092 was fur-
ther examined in the guinea pig aorta preparation. As it can be
seen in Figure 2, ME10092, in concentrations 3 × 10−6 to 10−4
M, caused a parallel rightward displacement of the dose re-
sponse curve of (-)adrenaline (3 × 10−9 – 3 × 10−5 M) without
affecting the slope of the maximal response. The slope of the
Schild plot computed from the data was 1.1 ± 0.1, suggesting
that ME10092 is a competitive antagonist. The Kb calculated
from the experiment was 4.6 µM, corresponding to a pA2
of 5.3.
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In the electrically stimulated isolated guinea pig ileum
organ bath experiments, ME10092 inhibited the contractions
of ileum with an IC50 of 25.3 µM (data not shown). Yohimbine
(3 µM) did not alter the inhibitory effect of ME10092 (data not
shown). In another experimental set-up we obtained inhibitory
dose response for (-)noradrenaline. We then observed that the
addition of 10 µM ME10092 caused a parallel shift of the
(-)noradrenaline inhibitory dose response curve to the right
(data not shown). Thus, these data indicate that ME10092 is a
weak 2-adrenoceptor antagonist on prejunctional 2-
adrenoceptors of the cholinergic neurones of the guinea pig
ileum. The Kb of ME100092 calculated from these data
amounted to 4.3 µM.
Determination of -Adrenoreceptor Binding
Activities of ME10092
Radioligand binding competition assays of ME10092
were performed using cell membranes expressing human 1A-,
2A-, 2B-, or 2C-adrenoceptors and appropriate labeled com-
FIGURE 2. Influence of ME10092 on the contractile response
of guinea pig aortic rings to (-)adrenaline. Values are expressed
as the percent of the rings’ maximally developed tension at the
highest adrenaline concentrations used. All values represent
the means  SEM of at least 3 independent experiments.
Insert shows the Schild plot calculated from the experimental
data.
FIGURE 1. Influence of ME10092 on the arterial pressure and
heart rate in the anesthetized rat. ME10092 in saline was ad-
ministrated i.v. through the cannulated femoral vein and
blood pressure recorded from the left carotid artery. Arterial
pressure (A) values are expressed in mm Hg, heart rate (B) in
percent of the basal rate (315 bpm). Shown is also the time
course for change of heart rate after ME10092 administration
in a single rat for 10 minutes after the compound administra-
tion (C). All values represent means  SEM of at least 3 inde-
pendent experiments. *P < 0.05 compared with control, **P <
0.01 compared with control.
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pounds. All obtained displacement curves were uniphasic,
with Hill coefficients close to unity. The non-specific binding
of [3H]-RX821002 was negligible, and that of [3H]-prazosin
less than 5% of total binding (data not shown). As can be seen
from Table 1, ME10092 showed 1 to 4 µM Kis to all -adre-
noceptor subtypes tested.
Inhibition of Xanthine Oxidase
Measuring the influence on formation of uric acid by
using an HPLC-based assay was used to assess the effect of
ME 10092 on xanthine oxidase mediated oxidation of xan-
thine. In control assays the speed of the uric acid formation
amounted to about 10 µM per min and unit of xanthine oxidase
(Fig. 3). Addition of 50 to 100 µM ME10092 inhibited the rate
of uric acid formation. As seen in Figure 3, ME10092 substan-
tially reduced the velocity at low concentrations of xanthine,
but did not alter it appreciably at higher concentrations of the
substrate. The competitive inhibition constant for ME10092
was estimated to be 24.4 µM, as it could be determined from
the plot of the enzyme reaction Km versus inhibitory concen-
trations of ME10092 (Fig. 3, inset).
Inhibitory Activity on NAD(P)H Oxidase
Mediated Oxyradical Formation
Lucigenin-dependent luminescence was registered from
samples containing rat brain membranes after addition of 200
µM of NADH or NADPH. The flavoenzyme inhibitor DPI14
was used to control the specificity of the assay. We found that
in the presence of 200 µM DPI the NADH and NADPH driven
luminescence was inhibited by 80% and 60%, respectively
(Fig. 4). As can be seen from the figure, ME10092 was a less
effective inhibitor, the inhibition caused at the highest dose
(500 µM) amounting to about 40% for both the NADH and
NADPH driven luminescence (Fig. 4).
Inhibition of Nitric Oxide Formation
in Rat Tissues In Vivo
The contents of NO were assayed in brain cortex, heart,
liver, and lungs taken from rats 1 hour after i.p. administration
of saline, or 5 and 10 mg/kg of ME10092, and spin trapping
reagents, by use of EPR (see Methods for details). As controls
served tissues from animals, treated identically, but without
receiving ME10092. In the heart the NO contents were too low
to be detectable both in control and ME10092-treated animals.
In liver and brain cortex we found ME10092 to decrease the
NO contents in a statistically significant manner (Fig. 5A). In
TABLE 1. Binding Activities, Ki, of ME10092 on Recombinant
Human -Adrenoreceptor Subtypes Determined in
Radiologand Binding Competition with [3H] Prazosin (1A)
and [3H] RX821002 (2A,B,C)
Receptor Ki (µM) ± SEM
1A 4.1 ± 0.3
2A 1.2 ± 0.1
2B 4.1 ± 0.3
2C 3.1 ± 0.5
FIGURE 3. Influence of ME10092 on xanthine oxidase-medi-
ated oxidation of xanthine. The formation of uric acid was
measured by HPLC 5 minutes after initiating the reaction. Val-
ues are expressed as µM of uric acid formed in 1 minute per
unit of xanthine oxidase. Squares, triangles, and rings indicate
control, ME10092 50 µM, and ME10092 100 µM, respectively.
All data points represent mean  standard deviation of at least
3 independent experiments. Insert shows the plot of the en-
zyme reaction Km calculated from the experimental data ver-
sus inhibitory concentrations of ME10092.
FIGURE 4. Influence of ME10092 on NAD(P)H oxidase-medi-
ated oxyradical formation in rat brain membranes. Chemilu-
minescence measurements were performed immediately after
addition of NADH or NADPH and lucigenin to membrane sus-
pensions preincubated with ME10092 or DPI. Values are ex-
pressed as percents of controls, with blanks subtracted. All
data points represent mean  standard deviation of at least
3 independent experiments performed with tetraplicates.
*P < 0.05 compared with control.
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the brain cortex ME10092 decreased the NO content to ap-
proximately half of the control level—that is from approxi-
mately 40 to approximately 20 ng/kg tissue, 1 hour after drug
administration. In the liver the effect was even more pro-
nounced, and the NO levels were decreased from 22 ng/kg in
controls to 13.2 and 11.9 ng/kg for, respectively, 5 and 10 mg/kg
of ME10092 administered. However, in lungs ME10092
did not statistically significantly decrease the NO content
(Fig. 5A).
The effect of ME10092 on NO was time dependent. As
seen from the series of experiments shown in Figure 5B, the
NO content in brain cortex and liver was significantly inhibited
1 hour after administration of ME10092. However, after 2
hours the NO contents were only slightly decreased in all tis-
sues, compared with the control levels. After 4 hours the NO
contents in the brain cortex had reached control values, but in
the liver it had become significantly elevated, from 20 to ap-
proximately 60 ng/kg tissue (Fig. 5B). In liver, the NO con-
tents were slightly elevated 1 and 2 hours after administration
of ME10092, but the effect was statistically significant only
after 4 hours. In rat cerebellum, testis, and kidney ME10092
affected the NO contents in a similar manner as in brain cortex
and liver (data not shown).
Inhibition of Nitric Oxide Synthase Activity
In Vitro
The influence of ME10092 on NOS was determined by
assessing the inhibition of NOS mediated 3H-arginine conver-
sion using in vitro assays with recombinant NOS isoforms. As
can bee seen in Figure 6, ME10092 exerted isoform-specific
inhibitory actions. ME10092 caused a dose-dependent inhibi-
tion of the activities of both nNOS and eNOS with IC50 values
230 µM and 30 µM, respectively. Thus, ME10092 appeared to
possess an 8-fold higher inhibitory activity for eNOS than for
nNOS. However, the iNOS activity was not influenced at all by
ME10092, even at the highest concentration of ME10092
tested, 1 mM (Fig. 6). The pre-incubation of NOS enzymes in
the presence of ME10092 before substrate addition did not sig-
nificantly influence the inhibitory profile of the compound
(data not shown).
DISCUSSION
We have shown previously that ME10092 affords a re-
markable cardioprotective action in an in vivo rat heart infarc-
tion model.5 In view of the powerful cardioprotective effect of
ME10092, while lacking any clear understanding on how this
effect is brought about, the present study was broadly under-
taken to clarify the pharmacology of ME10092. In some pre-
ceding studies we had found that the parent compound PR5
functions as an electron acceptor for xanthine oxidase during
anaerobic conditions, while during aerobic conditions it inhib-
its xanthine oxidase.3 PR5 shows strong protective effect in
heart infarction models.4 However, in vivo PR5 is very rapidly
metabolized to ME10092.5 This observation, and the virtu-
FIGURE 5. Dose-dependent (A), and time-dependent (B) in-
fluence of ME10092 on nitric oxide level in rat tissues. Values
are expressed as ng NO/g tissue. Data of (A) are obtained 1
hour after ME10092 administration. Data of (B) are obtained
for ME10092 10 mg/kg. All data points represent mean 
SEM of at least 6 independent experiments. *P < 0.05 com-
pared with control.
FIGURE 6. Influence of ME10092 on nitric oxide synthase iso-
form activity in vitro. Values are expressed as percents of
amount of citrulline formed without ME10092. All data points
represent mean  standard deviation of at least 3 indepen-
dent experiments performed in triplicates. *P < 0.05 compared
with control, **P < 0.01 compared with control.
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ally indistinguishable in vivo pharmacology of PR5 and
ME10092,5 lend support to the idea that xanthine oxidase-
mediated mechanisms might be responsible for the cardiopro-
tective effects of ME10092.5
It is generally accepted that oxyradical formation con-
tributes significantly to the size of the necrotic zone during
ischemia-reperfusion.15,16 If the formation of superoxide
could be effectively prevented during reperfusion, the tissue
damage would accordingly become reduced. Our previous
studies supply some evidence that antioxidative mechan-
isms are significant for the pharmacological actions of
ME10092. This is because we found PR5 treatment to lower
the contents of the oxidative stress marker malondialdehyde
in the ischemic heart tissue.4 This finding thus links an anti-
oxidant effect to ME10092, accepting the idea that the ob-
served actions of PR5 are indeed mediated by its metabolite
ME10092.
One major source for oxyradical formation may be xan-
thine oxidase.16,17 During an ischemia and reperfusion period
the xanthine dehydrogenase enzyme is converted to xanthine
oxidase, and the latter uses molecular oxygen as electron ac-
ceptor, leading to formation of toxic superoxide.15 Our present
biochemical studies show that ME10092 is only a weak inhibi-
tor on the xanthine oxidase enzyme, the Ki of ME10092 being
24 µM. This may be compared with the Ki of 0.7 µM reported
for allopurinol.18 An effect on xanthine oxidase of ME10092
seems therefore a less likely explanation for its cardioprotec-
tive properties. Moreover, even the role of xanthine oxidase
inhibition as a mechanism for cardiac protection during is-
chemia reperfusion has been questioned, and quite contradic-
tory data exist for a beneficial effect of allopurinol, and other
effective xanthine oxidase inhibitors, in experimental heart in-
farction.19,20 Real proof of pathophysiological role of xanthine
oxidase generated superoxide during ischemia-reperfusion re-
mains still elusive.
Another powerful enzymatic source of oxyradical for-
mation is NAD(P)H oxidases.21 Our results show that ME10092
inhibits free radical formation by this pathway to some extent.
Although inhibition of the activity is seen in the high micro-
molar concentration range it matches the concentration of the
cofactor NAD(P)H used in the assay. Still very high concen-
trations of ME10092 were needed to induce an effect, and the
compound is considerably less potent than the flavoenzyme
inhibitor DPI. It seems therefore quite unlikely that the cardio-
protective effect of ME10092 can be explained solely due to its
interaction with xanthine oxidase and NAD(P)H oxidase en-
zyme systems. However, the effect might still result in some
antioxidant actions in vivo.
Besides inducing cardioprotective actions, ME10092
also caused lowering of blood pressure and reductions of heart
rate in the normal artificial respirated anesthetized rat,5 possi-
bly indicating autonomic actions of the compound. ME10092
is a guanidine derivative, and guanidine derivatives, such as
guanabenz, have been synthesized and applied clinically for
use as centrally acting antihypertensive agents.22 Guanabenz is
known to stimulate 2-adrenergic receptors in the brainstem
and consequently to reduce the sympathetic outflow from the
CNS, which results in a hypotensive effect. The effect is simi-
lar to that elicited by clonidine and guanfacine.23–25 It is be-
lieved that 2-adrenergic agonists, due to their autonomic ef-
fects, reduce the energy demand in the heart, and that they
thereby could decrease the degenerative effects associated
with cardiac ischemia. Guanabenz has been shown to restore
the noradrenaline level and tyrosine hydroxylase activity in
hypertrophic rat hearts.7
We studied the -adrenoceptor activity of ME10092 us-
ing radioligand binding experiments on cells expressing re-
combinant -adrenoceptors. Our results show that ME10092
binds to all the human 1 and 2-adrenoceptor subtypes with
low micromolar affinity (Table 1). This may be compared with
the activity of guanabenz, which shows nanomolar affinities
for 2A- and 2B-adrenoceptors in rat kidney membranes.
26 A
known selective 1 and unselective -adrenoceptor antagonist
and potent antioxidant carvedilol shows high affinity (0,9–35
nM) for human recombinant adrenergic receptors and it also
significantly reduces the necrotic area in rabbit heart ischemia
and reperfusion model.27 The affinity constants obtained in the
binding experiments and functional studies of the present
study show that ME10092 is a much weaker antagonist on 1-
and 2-adrenoceptors than guanabenz and carvedilol. An
-agonistic mechanism of ME10092 can therefore be ruled
out. Possibly an 1-blocking activity could have a role for the
blood pressure-lowering effect of the compound, but -adre-
noceptor blocking effects can not explain the effect on heart
rate.
It has been reported that several bicyclic aroylguani-
dines act as very potent Na+/H+ exchange inhibitors and there-
by possess antiarrhythmic activity.28–30 The inhibition of the
Na+/H+ exchanger is considered to be a promising approach
for treating arrhythmia and cardiac dysfunction.31 We have
also tested the activity if ME10092 using a thrombocyte swell-
ing assay, wherein swelling can be induced by blockade of
the Na+/H+ exchanger. We found that ME10092 was a more
than 10-fold weaker inhibitor, compared with the Na+/H+ ex-
change inhibitor DMA (Dambrova et al, unpublished obser-
vations).
We here also tested the hypothesis that ME10092 influ-
ences NO-related events. Several recent studies describe inter-
actions of guanidine derivatives with subtypes of nitric oxide
synthase (NOS). Thus, it is known that aminoguanidine itself
is a selective inhibitor of inducible NOS.32 Guanabenz was
found to reduce the activity of rat penile NOS in vivo and in
vitro.33 It has also been shown that guanabenz may reduce neu-
ronal NOS in cells in culture by enhancing the proteolytic deg-
radation of NOS.34 Our results show that administration of
ME10092, in a dose-dependent manner, decreases the basal
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NO contents in the cerebral cortex and liver of the rat 1 to 2
hours after ME10092 administration. However, the reduction
of NO in rat lungs was not observed. By contrast, 4 hours after
the administration the NO levels had regained in all tissues
evaluated, and it had even become significantly elevated above
the control level in the liver and lungs (Fig. 5A). The later
finding possibly could be explained by a cytochrome-
dependent metabolism of guanidine derivatives with the oxi-
dation of corresponding N-hydroxyguanidine compound in the
liver microsomes and NO production.35,36
The role of NO in ischemic conditions remains contro-
versial. However, there is some evidence that NOS subtype
selective inhibition of NO synthesis may be useful for the treat-
ment of clinical conditions, including neurodegeneration, is-
chemic tissue injury, and inflammatory diseases.21,37,38 The
cardioprotective effect of ME10092 in our rat myocardial in-
farction studies was observed after 3 mg/kg i.v. administration
5 minutes before 60 minutes occlusion and 1.5 mg/kg admin-
istration 5 minutes before 120 minutes reperfusion.5 The in-
hibitory action on eNOS and nNOS 1 hour after ME10092 ad-
ministration thus constitutes an interesting observation that has
possible bearings on the observed in vivo pharmacological ac-
tions of ME10092. However, even though ME10092 possesses
a similar inhibitory effect on NO content in rat tissues in com-
parison to aminoguanidine and guanabenz,12 we show here
that in vitro it inhibits eNOS activity but not that of iNOS.
Thus, our data on NO inhibitory profile ME10092 does not
allow us to draw a final conclusion about the degree of the
involvement of NOS regulatory activity in the cardioprotective
action of ME10092.
In conclusion, our data give evidence that the cardiopro-
tective effect of ME10092 could be mediated through pharma-
cological mechanisms that include some modulation of NO
production, as well as possible inhibition of radical formation
during ischemia-reperfusion.
REFERENCES
1. Wattanapitayakul SK, Bauer JA. Oxidative pathways in cardiovascular
disease: roles, mechanisms, and therapeutic implications. Pharmacol
Ther. 2001;89:187–206.
2. Wang QD, Pernow J, Sjoquist PO, et al. Pharmacological possibilities for
protection against myocardial reperfusion injury. Cardiovasc Res. 2002;
55:25–37.
3. Dambrova M, Uhlen S, Welch CJ, et al. Identification of an N-hydroxy-
guanidine reducing activity of xanthine oxidase. Eur J Biochem. 1998;
257:178–184.
4. Veveris M, Dambrova M, Cirule H, et al. Cardioprotective effects of N-
hydroxyguanidine PR5 in myocardial ischaemia and reperfusion in rats.
Br J Pharmacol. 1999;128:1089–1097.
5. Dambrova M, Veveris M, Cirule H, et al. The novel guanidine ME10092
protects the heart during ischemia-reperfusion. Eur J Pharmacol. 2002;
445:105–113.
6. Dambrova M, Baumane L, Kiuru A, et al. N-Hydroxyguanidine com-
pound 1-(3,4-dimethoxy- 2-chlorobenzylideneamino)-3-hydroxyguani-
dine inhibits the xanthine oxidase mediated generation of superoxide radi-
cal. Arch Biochem Biophys. 2000;377:101–108.
7. Takechi S, Nomura A, Shimono H, et al. Recovery of cardiac norepineph-
rine concentration and tyrosine hydroxylase activity by the central alpha2-
adrenoceptor agonist guanabenz in rats with aortic constriction. J Cardio-
vasc Pharmacol. 1999;33:409–413.
8. Wikberg JES. The pharmacological classification of adrenergic a recep-
tors in the guinea pig. Nature. 1978;273:164–166.
9. Uhlén S, Dambrova M, Näsman J, et al. [3H]RS79948-197 binding to
human, rat, guinea pig and pig 2A-, 2B-, and 2C-adrenoceptors. Com-
parison with MK912, RX821002, rauwolscine and yohimbine. Eur
J Pharmacol. 1998;343:93–101.
10. J Esbenshade TA, Hirasawa A, Tsujimoto G, et al. Cloning of the human
alpha 1d-adrenergic receptor and inducible expression of three human
subtypes in SK-N-MC cells. Mol Pharmacol. 1995;47:977–985.
11. Li Y, Zhu H, Kuppusamy P, et al. Validation of lucigenin (bis-N-methyl-
acridinium) as a chemilumigenic probe for detecting superoxide anion
radical production by enzymatic and cellular systems. J Biol Chem. 1998;
273:2015–2023.
12. Dambrova M, Kirjanova O, Baumane L, et al. Investigation of in vivo
inhibitory effect of guanidine compounds on nitric oxide production in rat
tissues. J Physiol Pharmacol. 2003;54:339–347.
13. Baumane L, Dzintare M, Zvejniece L, et al. Increased synthesis of nitric
oxide in rat brain cortex due to halogenated volatile anesthetics confirmed
by EPR spectroscopy. Acta Anaesthesiol Scand. 2002;46:378–383.
14. Holland PC, Clark MG, Bloxham DP, et al. Mechanism of action of the
hypoglycemic agent diphenyleneiodonium. J Biol Chem. 1973;248:
6050–6056.
15. Hille R, Nishino T. Flavoprotein structure and mechanism. 4. Xanthine
oxidase and xanthine dehydrogenase. FASEB J. 1995;9:995–1003.
16. Saugstad OD. Role of xanthine oxidase and its inhibitor in hypoxia:
reoxygenation injury. Pediatrics. 1996;98:103–107.
17. Harrison R. Structure and function of xanthine oxidoreductase:where are
we now? Free Radic Biol Med. 2002; 33:774–797.
18. Elion GB. Enzymatic and metabolic studies with allopurinol. Ann Rheum
Dis. 1966;25:608–614.
19. Reimer KA, Jennings RB. Failure of the xanthine oxidase inhibitor allo-
purinol to limit infarct size after ischemia and reperfusion in dogs. Circu-
lation. 1985;71:1069–1075.
20. Hopson SB, Lust RM, Sun YS, et al. Allopurinol improves myocardial
reperfusion injury in a xanthine oxidase-free model. J Natl Med Assoc.
1995;87:480–484.
21. Ferdinandy P, Schulz R. Nitric oxide, superoxide, and peroxynitrite in
myocardial ischaemia- reperfusion injury and preconditioning. Br J Phar-
macol. 2003;138:532–543.
22. Bailey DM, DeGrazia CG, Lape HE, et al. Hydroxyguanidines. A new
class of antihypertensive agents. J Med Chem. 1973;16:151–156.
23. Shah RS, Walker BR, Vanov SK, et al. Guanabenz effects on blood pres-
sure and noninvasive parameters of cardiac performance in patients with
hypertension. Clin Pharmacol Ther. 1976;19:732–737.
24. Ledoux F, Welsch M, Steimer C, et al. Essai clinique du guanoxabenz, un
hypotenseur a action centrale et peripherique. Therapie. 1981;36:187–
191.
25. van Zwieten PA. Centrally acting antihypertensives: a renaissance of
interest. Mechanisms and haemodynamics. J Hypertens Suppl. 1997;15:
S3–S8.
26. Uhlen S, Wikberg JE. Delineation of rat kidney alpha 2A- and alpha 2B-
adrenoceptors with [3H]RX821002 radioligand binding: computer mod-
elling reveals that guanfacine is an alpha 2A-selective compound. Eur
J Pharmacol. 1991;202:235–243.
27. Feuerstein G, Liu GL, Yue TL, et al. Comparison of metoprolol and carve-
dilol pharmacology and cardioprotection in rabbit ischemia and reperfu-
sion model. Eur J Pharmacol. 1998;351:341–350.
28. Yamamoto T, Hori M, Watanabe I, et al. Structural requirements for po-
tential Na/H exchange inhibitors obtained from quantitative structure-
activity relationships of monocyclic and bicyclic aroylguanidines. Chem
Pharm Bull. 1997;45:1282–1286.
29. Baumgarth M, Beier N, Gericke R. Bicyclic acylguanidine Na+/H+ anti-
porter inhibitors. J Med Chem. 1998;41:3736–3747.
30. Banno H, Fujiwara J, Hosoya J, et al. Effects of MS-31-038, a novel
J Cardiovasc Pharmacol • Volume 44, Number 2, August 2004 Pharmacological Mechanisms of ME10092
© 2004 Lippincott Williams & Wilkins 185
Na(+)-H+ exchange inhibitor, on the myocardial infarct size in rats
after postischemic administration. Arzneimittelforschung. 1999;49:304–
310.
31. Levitsky J, Gurell D, Frishman WH. Sodium ion/hydrogen ion exchange
inhibition: a new pharmacologic approach to myocardial ischemia and
reperfusion injury. J Clin Pharmacol. 1998;38:887–897.
32. Southan GJ, Szabo C. Selective pharmacological inhibition of distinct ni-
tric oxide synthase isoforms. Biochem Pharmacol. 1996;51:383–394.
33. Nakatsuka M, Nakatsuka K, Osawa Y. Metabolism-based inactivation of
penile nitric oxide synthase activity by guanabenz. Drug Metab Dispos.
1998;26:497–501.
34. Noguchi S, Jianmongkol S, Bender AT, et al. Guanabenz-mediated inac-
tivation and enhanced proteolytic degradation of neuronal nitric-oxide
synthase. J Biol Chem. 2000;275:2376–2380.
35. Clement B, Demesmaeker M. Formation of guanoxabenz from guanabenz
in human liver. A new metabolic marker for CYP1A2. Drug Metab Dis-
pos. 1997;25:1266–1271.
36. Mansuy D, Boucher JL, Clement B. On the mechanism of nitric oxide
formation upon oxidative cleavage of C = N(OH) bonds by NO-synthases
and cytochromes P450. Biochimie. 1995;77:661–667.
37. Alderton WK, Cooper CE, Knowles RG. Nitric oxide synthases: structure
function and inhibition. Biochem J. 2001;357:593–615.
38. Vallence P, Leiper J. Blocking of NO synthesis: how where and why?
Nature Rev Drug Disc. 2002;1:939–950.
Dambrova et al J Cardiovasc Pharmacol • Volume 44, Number 2, August 2004
186 © 2004 Lippincott Williams & Wilkins
